Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Metoclopramide HCl (Maxolon, AHR3070-C, AHR 3070-C, Metozolv, Reglan), the hydrochloride salt of Metoclopramide, is a potent and selective dopamine D2 receptor antagonist used as a medication for treating stomach and esophageal problems such as nausea and vomiting. It can aid in the relief of gastroesophageal reflux disease and help those whose stomach emptying is delayed as a result of diabetes or surgery. Furthermore, it is also effective in treating migraine headaches.
Targets |
5-HT3 Receptor ( IC50 = 308 nM ); D2 Receptor ( IC50 = 483 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
Metoclopramide (6.7 µg/g; once daily, subcutaneously for 50 days) During every stage of the estrous cycle, hydrochloride dramatically raises the pituitary gland's lactotroph cell count and volume[4].
Metoclopramide hydrochloride (5–40 mg/kg; intraperitoneal) causes catalepsy and antagonistic Mice's tendency to climb their cages was induced by apomorphine[5]. Metoclopramide (1.25-2.5 mg/kg; i.p.) hydrochloride induces in mice a stereotyped behavior of climbing cages[5]. |
|
Animal Protocol |
Adult, virgin female mice of the Swiss EPM-1 strain
6.7 µg/g S.c. daily for 50 days |
|
References |
|
Molecular Formula |
C14H23CL2N3O2
|
|
---|---|---|
Molecular Weight |
336.26
|
|
Exact Mass |
335.12
|
|
Elemental Analysis |
C, 50.01; H, 6.89; Cl, 21.09; N, 12.50; O, 9.52
|
|
CAS # |
7232-21-5
|
|
Related CAS # |
Metoclopramide; 364-62-5; Metoclopramide hydrochloride hydrate; 54143-57-6
|
|
Appearance |
Solid powder
|
|
SMILES |
CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.Cl
|
|
InChi Key |
RVFUNJWWXKCWNS-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C14H22ClN3O2.ClH/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3;/h8-9H,4-7,16H2,1-3H3,(H,17,19);1H
|
|
Chemical Name |
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9739 mL | 14.8694 mL | 29.7389 mL | |
5 mM | 0.5948 mL | 2.9739 mL | 5.9478 mL | |
10 mM | 0.2974 mL | 1.4869 mL | 2.9739 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02965963 | Active Recruiting |
Drug: Dopamine Drug: Metoclopramide Drug: Placebos Other: Rest |
Health | University of Alberta | December 2016 | Not Applicable |
NCT05746377 | Recruiting | Drug: Metoclopramide 10mg Drug: Saline |
Upper GI Bleeding Bleeds Gastric Bleed Ulcer |
Mercy Health System | May 20, 2023 | Phase 4 |
NCT05222646 | Recruiting | Drug: Metoclopramide | Duration of Labour | Uwakwe Emmanuel Chijioke | January 3, 2022 | Phase 1 |
NCT05102591 | Recruiting | Drug: Ketorolac Drug: Metoclopramide Drug: Placebo |
Migraine Disorders | University of Calgary | February 22, 2022 | Phase 3 |
NCT05533281 | Recruiting | Drug: tropisetron Drug: metoclopramide Drug: dexamethasone |
Nausea and Vomiting | The Second Affiliated Hospital of Chongqing Medical University |
September 15, 2022 | Early Phase 1 |
Immunohistochemical localization of prolactin in adenohypophyseal lactotrophs in female control (Ctr) mice or mice treated with metoclopramide (HPrl) in the estrous phase. Clinics (Sao Paulo) . 2011;66(6):1101-4. td> |